Recurrent Glioblastoma Multiforme (GBM) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Recurrent Glioblastoma Multiforme (GBM) Clinical Trial Market Report Overview
Recurrent Glioblastoma multiforme (GBM) clinical trial market research report provides top line data relating to the clinical trials on Recurrent Glioblastoma multiforme (GBM). The GBM Clinical Trial market research report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
Key Regions | North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America |
Key Countries | The US, China, Canada, France, Germany, Italy, Australia, Spain, the UK, and The Netherlands |
Key G7 Countries | United States, Japan, France, Italy, Germany, United Kingdom, and Canada |
Key E7 Countries | China, Russia, India, Brazil, Turkey, Mexico, and Indonesia |
Key Sponsors | Merck & Co Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Co, AstraZeneca Plc, Eli Lilly and Co, Amgen Inc, NovoCure Ltd, and Eisai Co Ltd |
Recurrent GBM Clinical Trial Market Segmentation by Regions
The key regions in the Recurrent Glioblastoma multiforme (GBM) clinical trial market are North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America. North America had the highest number of clinical trials in 2022.
Recurrent Glioblastoma multiforme (GBM) Clinical Trial Market Analysis by Regions, 2022 (%)
For more regional insights into the Recurrent GBM clinical trial market, download a free report sample
Recurrent GBM Clinical Trial Market Segmentation by Countries
The key countries in the Recurrent Glioblastoma multiforme (GBM) clinical trial market are the US, China, Canada, France, Germany, Italy, Australia, Spain, the UK, and the Netherlands. The US had the highest number of clinical trials as of May 2022.
Recurrent GBM Clinical Trial Market Segmentation by G7 Countries
The G7 countries are the US, Japan, France, Italy, Germany, United Kingdom, and Canada. Amongst them, the US had the highest number of clinical trials in the GBM clinical trial market in 2022. Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the US had the highest proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology clinical trials as of May 2022.
Recurrent Glioblastoma multiforme (GBM) Clinical Trial Market Analysis by G7 Countries, 2022 (%)
For more G7 country insights into the Recurrent GBM clinical trial market, download a free report sample
Recurrent GBM Clinical Trial Market Segmentation by E7 Countries
The E7 countries are China, Russia, India, Brazil, Turkey, Mexico, and Indonesia. China had the highest number of clinical trials in 2022. Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil had the highest proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology clinical trials as of May 2022.
Recurrent Glioblastoma multiforme (GBM) Clinical Trial Market Analysis by E7 Countries, 2022 (%)
For more E7 country insights into the Recurrent GBM clinical trial market, download a free report sample
Recurrent GBM Clinical Trial Market – Competitive Landscape
The key sponsors in the Recurrent Glioblastoma multiforme (GBM) clinical trial market are Merck & Co Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Co, AstraZeneca Plc, Eli Lilly and Co, Amgen Inc, NovoCure Ltd, and Eisai Co Ltd.
Recurrent Glioblastoma multiforme (GBM) Clinical Trial Market Analysis by Sponsors, 2022 (%)
To know more about the sponsors in the Recurrent GBM clinical trial market, download a free report sample
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc
Bristol-Myers Squibb Co
AstraZeneca Plc
Eli Lilly and Co
Amgen Inc
NovoCure Ltd
Eisai Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key regions in the Recurrent Glioblastoma multiforme (GBM) clinical trial market?
The key regions in the Recurrent Glioblastoma multiforme (GBM) clinical trial market are North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America. North America has the highest number of clinical trials.
-
What are the G7 countries landscape in the Recurrent Glioblastoma multiforme (GBM) clinical trial market?
The G7 countries are United States, Japan, France, Italy, Germany, United Kingdom, and Canada.
-
What are the E7 countries landscape in the Recurrent Glioblastoma multiforme (GBM) clinical trial market?
The E7 countries are China, Russia, India, Brazil, Turkey, Mexico, and Indonesia.
-
Who are the key sponsors in the Recurrent Glioblastoma multiforme (GBM) clinical trial market?
The key sponsors in the Recurrent Glioblastoma multiforme (GBM) clinical trial market are Merck & Co Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Co, AstraZeneca Plc, Eli Lilly and Co, Amgen Inc, NovoCure Ltd, and Eisai Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.